How Ketamine Spawned a $1.7 Billion J&J Blockbuster Drug

Johnson & Johnson’s Spravato has evolved from a difficult-to-deliver, heavily regulated long shot into a billion-dollar drug, signaling meaningful commercial success. The article highlights how the ketamine-derived nasal spray helped pioneer a new model for depression treatment, with implications for the company’s mental health portfolio and the broader healthcare sector. While the piece is largely retrospective rather than event-driven, it underscores a durable growth story in a regulated therapeutic category.

Analysis

Johnson & Johnson’s Spravato has evolved from a difficult-to-deliver, heavily regulated long shot into a billion-dollar drug, signaling meaningful commercial success. The article highlights how the ketamine-derived nasal spray helped pioneer a new model for depression treatment, with implications for the company’s mental health portfolio and the broader healthcare sector. While the piece is largely retrospective rather than event-driven, it underscores a durable growth story in a regulated therapeutic category.